BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16555434)

  • 1. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
    Vose J
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
    Vose JM
    Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
    Winter JN
    Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA; Connors JM
    Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
    J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular lymphoma: time for a re-think?
    Gandhi MK; Marcus RE
    Blood Rev; 2005 May; 19(3):165-78. PubMed ID: 15748964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indolent lymphomas: current and emerging treatment approaches.
    Maloney D; Kahl BS; Dreyling M
    Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
    Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M
    Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment for malignant lymphomas].
    Usui N
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2191-9. PubMed ID: 18079619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.
    Villanueva ML; Vose JM
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):521-30. PubMed ID: 17147239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
    Martin P; Furman RR; Coleman M; Leonard JP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
    Visser OJ; Zijlstra JM; van Dongen GA; Huijgens PC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2324-8. PubMed ID: 16261710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.